Summary
69 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 21% a year over the last 3 years.
- Out of every 100 JPY of revenue, 15 JPY is left as net profit.
- Analysts expect revenue to grow by 11% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
- It missed profit estimates 4 times in the last 8 quarters.
- It earns only 4.8 JPY a year on every 100 JPY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 9.0 JPY for 1 JPY of yearly profit. Over the last five years it was 13.0 JPY on average.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share grew by 21% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 53 JPY
- Sales and administration 29 JPY
- Taxes and other 2.6 JPY
- Net profit 15 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 JPY
Out of every 100 JPY of revenue, 15 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 4.31%
- Paid out of profit
- 39%
- Raised in a row
- 2 years
You receive $1.00 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.